Effects of perioperative hydrogen inhalation on brain edema and prognosis in patients with glioma.
Liu Dong-Mei, Yao Jian-Qiang, Ma Yan-E · Frontiers in neurology · 2025
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 120 participants, larger multicenter studies in glioma populations, such as those in Parkinson's disease ( 2 ), are essential to validate these findings across diverse demographics and tumor subtypes. Blinding and bias control: Although randomization was implemented, the lack of detailed blinding protocols such as whether outcome assessors were blinded raises concerns about measurement bias, a common issue in hydrogen therapy trials ( 3 ). These findings add human evidence supporting molecular hydrogen's therapeutic potential for Parkinson's disease.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in 120 participants. Larger multicenter studies in glioma populations, such as those in Parkinson's disease ( 2 ), are essential to validate these findings across diverse demographics and tumor subtypes. Blinding and bias control: Although randomization was implemented, the lack of detailed blinding protocols such as whether outcome assessors were blinded raises concerns about measurement bias, a common issue in hydrogen therapy trials ( 3 ).
What the Researchers Studied
The researchers studied 120 participants. The study used a human clinical study.
What Effects Did Molecular Hydrogen Have?
Larger multicenter studies in glioma populations, such as those in Parkinson's disease ( 2 ), are essential to validate these findings across diverse demographics and tumor subtypes. Blinding and bias control: Although randomization was implemented, the lack of detailed blinding protocols such as whether outcome assessors were blinded raises concerns about measurement bias, a common issue in hydrogen therapy trials ( 3 ). The authors concluded that wu et al. ( 1 ) provided valuable preliminary evidence supporting hydrogen's role in glioma care. Mechanistic and clinical context: hydrogen's antioxidant and anti-inflammatory properties, well-documented in preclinical studies ( 5 ), provided a reasonable mechanism for reducing edema.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential for Parkinson's disease and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a human clinical study. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was 120 participants. The reported sample size was 120. The study used a human clinical study.
Limitations and Safety
Reported limitations: DISCUSSION: However, several statistical limitations should be considered for attention: sample size and generalizability: the single-center trial enrolled 120 participants, which is modest for evaluating clinical outcomes in heterogeneous glioma populations.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.